Patrick Vermersch is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology.
According to data from OpenAlex, Patrick Vermersch has authored 391 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 227 papers in Pathology and Forensic Medicine, 116 papers in Neurology and 73 papers in Oncology. Recurrent topics in Patrick Vermersch's work include Multiple Sclerosis Research Studies (208 papers), Peripheral Neuropathies and Disorders (80 papers) and Polyomavirus and related diseases (59 papers). Patrick Vermersch is often cited by papers focused on Multiple Sclerosis Research Studies (208 papers), Peripheral Neuropathies and Disorders (80 papers) and Polyomavirus and related diseases (59 papers). Patrick Vermersch collaborates with scholars based in France, United States and Germany. Patrick Vermersch's co-authors include J. de Sèze, Didier Leys, Tanya Stojkovic, M Steinling, Jean‐Pierre Pruvo, Frederik Barkhof, Philip Scheltens, Jaap Valk, Hélène Zéphir and Gavin Giovannoni and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.
In The Last Decade
Patrick Vermersch
375 papers
receiving
13.3k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.
19921.3k citationsPatrick Vermersch et al.profile →
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging
1993787 citationsJean‐Pierre Pruvo, Patrick Vermersch et al.profile →
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
2010689 citationsGavin Giovannoni, Gıancarlo Comı et al.profile →
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease
1999625 citationsPatrick Vermersch, Florence Pasquier et al.Neurologyprofile →
Neuromyelitis Optica and Non–Organ-Specific Autoimmunity
2008448 citationsJ. de Sèze, Patrick Vermersch et al.profile →
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
202526 citationsCelia Oreja‐Guevara, Gavin Giovannoni et al.profile →
Author Peers
Peers are selected by citation overlap in the author's most active subfields.
citations ·
hero ref
Countries citing papers authored by Patrick Vermersch
Since
Specialization
Citations
This map shows the geographic impact of Patrick Vermersch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Vermersch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Vermersch more than expected).
Fields of papers citing papers by Patrick Vermersch
This network shows the impact of papers produced by Patrick Vermersch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Vermersch. The network helps show where Patrick Vermersch may publish in the future.
Co-authorship network of co-authors of Patrick Vermersch
This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Vermersch.
A scholar is included among the top collaborators of Patrick Vermersch based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Patrick Vermersch. Patrick Vermersch is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Vermersch, Patrick, Giacomo P. Comi, Gavin Giovannoni, et al.. (2011). Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study. UCL Discovery (University College London).1 indexed citations
Rieckmann, Peter, G. Comi, Sandra Cook, et al.. (2009). Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study. UCL Discovery (University College London).9 indexed citations
15.
Vermersch, Patrick. (2008). Immunologie de la sclérose en plaques : évolution des concepts. Revue Neurologique. 164.1 indexed citations
16.
Sèze, J. de, et al.. (2006). Syndrome de Guillain-Barré sévère et grossesse : deux cas d’amélioration rapide en post-partum: Hypotheèses étiopathogéniques et revue de la littérature. Revue Neurologique. 162(3). 358–362.3 indexed citations
17.
Sèze, J. de, Sylvain Dubucquoi, A.L. Fauchais, et al.. (2004). Autoantibodies against alpha-fodrin in Sjögren's syndrome with neurological manifestations.. PubMed. 31(3). 500–3.25 indexed citations
18.
Vermersch, Patrick. (2001). Actualités thérapeutiques dans la sclérose en plaques. 7(2). 157–162.1 indexed citations
19.
Vermersch, Patrick, et al.. (1993). [Adrenoleukomyeloneuropathy in an adult].. PubMed. 149(3). 230–2.1 indexed citations
20.
Vermersch, Patrick. (1984). L'observation systématique dans l'étude du fonctionnement cognitif. Psychologie Française. 29. 297–302.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.